Pay in 4 interest-free payments of $7.37 Learn more
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17
5 Therapeutic implications and challenges The delineation of the ferroptosis-immune-metabolic axis in COPD unveils a new frontier for therapeutic intervention
OASIS trials: establishing effective doses Phase 2 OASIS 1 findings: Tested multiple dose levels: 0.3mg, 0.6mg, 1.2mg, 2.4mg, 4.5mg weekly Duration: 26 weeks Primary endpoint: Weight loss at each dose Dose-response results: 0.3mg weekly: ~4% body weight loss 0.6mg weekly: ~6% body weight loss 1.2mg weekly: ~8% body weight loss 2.4mg weekly: ~10% body weight loss 4.5mg weekly: ~12% body weight loss Key insight: Clear dose-response relationship
119 ScaliseM.GalluccioM.AccardiR.CornetI.TommasinoM.IndiveriC
Confirm that volume and the correct syringe with the dispensing pharmacist before use
track down the events through which the probiotic Lactobacillus GG releases soluble molecules that in turn activate the p38 MAPK pathway that synthesizes heat-shock proteins to shield the intestinal epithelial cells from damage (Tao et al., 2006)
R.de TorresS
US$ 23.81
US$ 29.65
US$ 24.26
US$ 26.52
